Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024)
Ginkgo Bioworks Holdings posted quarterly Asset Writedowns and Impairment of $47.9 million for Q2 2024, up 431.76% year-on-year from $9.0 million in Q3 2023, and down 60.58% on a QoQ basis from $121.4 million in Q4 2023.
Ginkgo Bioworks Holdings (DNA) has 2 years of Asset Writedowns and Impairment data on file, last reported at $47.9 million in Q2 2024.
- For the quarter ending Q2 2024, Asset Writedowns and Impairment rose 431.76% year-over-year to $47.9 million; the trailing twelve-month figure through Sep 2025 stood at $47.9 million (down 83.01% YoY), and the FY2024 full-year result was $4.8 million, down 96.03% from the prior year.
- Asset Writedowns and Impairment for Q2 2024 stood at $47.9 million, down from $121.4 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $121.4 million in Q4 2023 and bottomed at $9.0 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 47.86 Mn |
| Jun 30, 2024 | 47.86 Mn |
| Dec 31, 2023 | 121.40 Mn |
| Dec 31, 2023 | 121.40 Mn |
| Sep 30, 2023 | 112.40 Mn |
| Sep 30, 2023 | 112.40 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Jun 30, 2023 | 9.00 Mn |